Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

<h2>Clinical Practice Points</h2> <ul><li>•No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung cancer (NSCLC) and MET-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).</li><li>•This case series describes real-world outcomes with tepotinib, a selective MET-TKI, in combination with EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC and resistance to EGFR-TKIs.</li><li>•Among the 25 patients included, tepotinib was given in combination with a range of EGFR-TKIs (osimertinib, n = 18; gefitinib, n = 5; dacomitinib, n = 1; afatinib, n = 1) as second (n = 8), third (n = 9), or fourth-or-later (n = 8) line therapy.</li><li>•Tepotinib plus EGFR-TKIs demonstrated clinical benefit per physician's assessment in 23/25 patients, with a partial response in 15/25 patients.</li><li>•Tepotinib plus EGFR-TKIs showed favorable tolerability that was consistent with previous observations, with edema reported as the most common tepotinib-related adverse event (14/25 patients).</li><li>•This case series, including patients with several prior treatment lines, suggest tepotinib plus an EGFR-TKI as a potential chemotherapy-sparing, oral targeted treatment option for patients with EGFR‑mutated, MET-altered NSCLC after progression on EGFR‑TKIs.</li></ul>

Authors

Institutions

Publication Details

Journal
Clinical Lung Cancer
Published
2025-02-21
DOI
https://doi.org/10.1016/j.cllc.2025.02.013
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

Kirsty Lee, Lizza Hendriks, Wei‐Sen Lam, Charlotte De Bondt et al.
Clinical Lung Cancer
Lung Cancer Treatments and Mutations
article

Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

Kirsty Lee, Lizza Hendriks, Wei‐Sen Lam, Charlotte De Bondt, Xiuning Le, Anna Eisert, Anthonie J. van der Wekken, Iacopo Petrini, Soetkin Vlassak, David Farrugia, Karin Berghoff, Lye Mun Tho, Jens Samol, Hazel O’Sullivan, M. Hochmair, Tsung‐Ying Yang, Sanjay Popat, Julien Mazieres, María González‐Cao, Gee‐Chen Chang, Oscar S.H. Chan, Te‐Chun Hsia, Patrizia Froesch, Kirti Joshi, Niki Karachaliou, Nirmal Vivek Raut, Ulrike Himpe, Azura Rozila Ahmad
article en

Abstract

<h2>Clinical Practice Points</h2> <ul><li>•No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung cancer (NSCLC) and MET-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).</li><li>•This case series describes real-world outcomes with tepotinib, a selective MET-TKI, in combination with EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC and resistance to EGFR-TKIs.</li><li>•Among the 25 patients included, tepotinib was given in combination with a range of EGFR-TKIs (osimertinib, n = 18; gefitinib, n = 5; dacomitinib, n = 1; afatinib, n = 1) as second (n = 8), third (n = 9), or fourth-or-later (n = 8) line therapy.</li><li>•Tepotinib plus EGFR-TKIs demonstrated clinical benefit per physician's assessment in 23/25 patients, with a partial response in 15/25 patients.</li><li>•Tepotinib plus EGFR-TKIs showed favorable tolerability that was consistent with previous observations, with edema reported as the most common tepotinib-related adverse event (14/25 patients).</li><li>•This case series, including patients with several prior treatment lines, suggest tepotinib plus an EGFR-TKI as a potential chemotherapy-sparing, oral targeted treatment option for patients with EGFR‑mutated, MET-altered NSCLC after progression on EGFR‑TKIs.</li></ul>

Clinical Lung CancerVol. 26(4)
University of Pisa (IT), Cheltenham General Hospital (GB), Royal Marsden NHS Foundation Trust (GB), University Medical Center Groningen (NL), The University of Texas MD Anderson Cancer Center (US), Université Toulouse III - Paul Sabatier (FR), Johns Hopkins University (US), Merck KGaA, Darmstadt (Germany) (DE), University of Groningen (NL), Université Fédérale de Toulouse Midi-Pyrénées (FR), China Medical University (TW), Hospital Kuala Lumpur (MY), Maastricht University Medical Centre (NL), Cork University Hospital (IE), Tan Tock Seng Hospital (SG), Düsseldorf University Hospital (DE), Taichung Veterans General Hospital (TW), Department of the Premier and Cabinet (AU), Integrated Oncology (United States) (US), Instituto Oncológico Dr. Rosell (ES), Ente Ospedaliero Cantonale (CH), Antwerp University Hospital (BE), Bhaktivedanta Hospital & Research Institute (IN), Chung Shan Medical University Hospital (TW), Prince of Wales Hospital (CN), China Medical University Hospital (TW), AZ Delta (BE), University Hospital Cologne (DE), Heinrich Heine University Düsseldorf (DE), Chung Shan Medical University (TW)
Mesothelioma Applied Research Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Ariad Pharmaceuticals, Celgene, Regeneron Pharmaceuticals, Merck KGaA, Les Laboratories Pierre Fabre, BeiGene, Eisai, Ipsen, Genentech, EMD Serono, Daiichi Sankyo Europe
Openalex Percentile: Top 95%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.